ADHD medication shortages in France — what to do, concretely

The problem isn’t in your head

Since 2023, thousands of French ADHD patients have lived through an anxious experience: arriving at the pharmacy, handing over the prescription, and hearing “we don’t have any”. Then calling other pharmacies. Then learning it’s national. Then dreading the same thing next month.

This page exists to give you a clear view of what’s happening, what’s being done, and what you can do. Without minimising, without dramatising.

What’s happening, concretely

Timeline of the tensions

The causes explained by ANSM and laboratories

What’s rarely said

Source on the explosion of prescriptions: the F2RSM Psy study ^[9] documented methylphenidate use growth in adults in Hauts-de-France between 2014 and 2025 — a continuous, significant rise.

Products affected

Status at start of 2026

The situation evolves fast. For the up-to-date version, consult:

• ANSM: shortages section on ansm.sante.fr.
• HyperSupers TDAH France: regular update ^[4] .
• Your pharmacy.

Overall, as of 8 January 2026 ^[1] :

• Methylphenidate (Ritaline, Concerta, Quasym, Medikinet and generics): persistent tensions for several years, gradual improvement reported. Visibility limited beyond March 2026.
• Strattera (Lilly): manufacturing discontinuation planned, temporary reopening of initiations on 27 February 2025, then complete stop February 2026 ^[5] . Atomoxetin Stada and Zentiva generics available under derogatory access.
• Elvanse (Takeda): accessible under AAC. Occasional suspensions on some doses (notably 20 mg, 30 mg) ^[6] .
• XURTA (HAC Pharma): recent marketing authorisation (September 2025), gradual ramp-up in availability.

What you can do — the practical guide

Prevention (before it hits you)

If your regular pharmacy no longer has your treatment

What ANSM recommends to pharmacists ^[8] :

What NOT to do

Clinical alternatives — with your prescriber

Important: no switch should happen without your prescriber’s explicit agreement. Equivalences aren’t always direct.

Between methylphenidate formulations

• Ritaline IR (3-4 h) can temporarily replace Ritaline LP by taking 2-3 doses across the day (rarely satisfactory long-term).
• Switching Ritaline LP ↔ Quasym LP ↔ Concerta LP ↔ Medikinet LP: doses not strictly equivalent, adjustments needed.
• Switch from brand to generic (Mylan, Arrow, Biogaran, Viatris): generally well tolerated but not guaranteed.

Between molecules

• Methylphenidate → Lisdexamfetamine (XURTA / compassionate Elvanse): different family, new evaluation.
• Methylphenidate → Atomoxetine: switch to non-stimulant, 4-8 week delay for full effect.
• These switches require a consultation, sometimes a new initiation by a specialist.

If really no immediate alternative

Discuss with your prescriber a framed temporary break, non-medication coping strategies (accommodations, CBT, structured physical activity, sleep ++), and plan restart as soon as available.

I went through a 3-week shortage in 2024. My psychiatrist had anticipated: we’d agreed that if Quasym LP was missing, we’d temporarily switch to Concerta. The transition wasn’t ideal — 5 days of fog — but much better than a cold stop.

What institutions are trying to do

ANSM side

Political side

Parliamentary questions ^[7] have challenged the government on the shortages. The Ministry of Health has confirmed monitoring the file and asked laboratories for additional measures. Tangible results remain gradual.

Association side

HyperSupers TDAH France ^[4] maintains a regular monitoring page, channels reports from the ground, and advocates with authorities. Subscribing is one of the useful actions if you’re a patient or carer.

Honest questions we ask

”Will the shortage last much longer?”

Honest answer: we don’t know for sure. ANSM speaks of gradual improvement early 2026 ^[1] but with limited visibility beyond March. Demand continues to grow (rising ADHD diagnoses). Production capacity takes time to adjust.

”Are generics as effective as Ritaline or Concerta?”

On average, yes — same active ingredients, bioequivalence required for marketing authorisation. Individually, some people report differences (formulation, excipients, subjective duration). Report to your prescriber if the switch causes problems, without making it a rule.

”Can I legally order methylphenidate from abroad?”

No, not for a private individual. Importing a controlled substance without authorisation is an offence. Some French patients living near the Belgian, German or Swiss border get their treatment via a local doctor when they work there — individual situation, to evaluate legally with your doctor.

”My employer asks why I’m less productive, is it related?”

Possibly. Don’t over-share if you don’t want to — you can say “treatment being adjusted”. Someone managing ADHD with treatment AND experiencing a 2-week shortage can legitimately see their performance fluctuate. You don’t have to apologise for a supply system failure.

Where to follow up-to-date info

Signals for prompt consultation

Takeaways

Go further

• Methylphenidate — full detail
• Lisdexamfetamine (Elvanse / XURTA) — the other option
• Atomoxetine (Strattera) — the non-stimulant
• Managing side effects — practical guide
• HyperSupers TDAH France — association website
• ANSM — French National Agency for Medicines Safety